07 Sep New In vivo syngeneic subcutaneous CT26 colon tumor model Shuttle session
Because of the success of previous shuttle sessions, which offered the opportunity to run efficacy studies in a cost-saving manner, Explicyte is planning a new shuttle on the CT26 tumor-bearing mouse model, which will take place in October.
In this shuttle, our well-characterized syngeneic CT26 colon tumor-bearing mouse model will be used through standardized study protocols, for the evaluation of potential anti-tumor benefits from drug combinations with reference immune checkpoint inhibitors or chemotherapies.
As cost-effective studies, only experimental test groups will be at the Sponsor’s expense, while vehicle- and reference-treated groups will be covered by Explicyte.
Contact us to book a seat & test your candidate compound.
Differential responses of CT26 tumor-bearing mouse model to immune checkpoint inhibitors and to 5-Fluorouracil (5FU) chemotherapy. Mice are challenged with CT26 tumor cells and exposed to either anti-CTLA4, anti-PD1 or anti-PDL1 antibodies, or to 5FU treatment. Contrarily to the strong response to anti-CTLA4 antibody, CT26 tumor is partially responsive to PD1/PDL-1 blockade. A partial response is also observed upon 5FU treatment.
Shuttle for efficacy assessment on 6-week experimental session
· Model / Strain: CT26 colon tumor-bearing model / Balb/c mice
· Readouts: Tumor growth / Body weight / Survival
· Standard reference: PD1, PDL1, or CTLA4 monoclonal antibody, or 5FU treatment
· Group size: At least 10 mice per group
Optional analyses: Satellite studies for immune response profiling and MoA delineation (flow cytometry, RT-qPCR, immunohistochemistry…). Contact us for further information.
In vivo syngeneic subcutaneous CT26 colon tumor model Shuttle session